STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
STAT•Ed Silverman11 SeptSTAT — page 3
70 articlesstatnews.com ↗
Coverage, page 3
page 3 of 4STAT•Ed Silverman11 Sept
Medicaid will let states use ‘tiers’ to determine medical frailty
New Medicaid rules use allow use of tiers to determine work exemptions. Advocates fear complex guidelines could cause patients to lose insurance.
STAT•Isabella Cueto11 Sept
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through mergers and acquisitions
STAT•Ed Silverman11 Sept
STAT+: Cancer drug shortages keep disrupting patient care
Platinum chemotherapy's long-term effects, surprising heart failure drug failures, and more biotech news from The Readout
STAT•Meghana Keshavan11 Sept
Boycott launched against American Diabetes Association includes journal
Trump's $500 Obamacare promise, childhood cancer treatment with long-term risks, and more health news
STAT•Chelsea Cirruzzo, Helen Branswell,and Elizabeth Cooney11 Sept
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.
STAT•Allison DeAngelis and Adam Feuerstein11 Sept
Opinion: I’m a public health communications consultant. Pro-vaccine advocacy needs more fun
“Somewhere along the way, we forgot how to celebrate vaccines,” writes public health communications consultant Adam Zimmerman.
STAT•Adam Zimmerman11 Sept
Opinion: I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over
“For thousands of families, the Sept. 11 attack did not end when the fires were extinguished. It simply changed form,” writes Raja Flores.
STAT•Raja Flores11 Sept
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
A newly approved AI tool can scan EKGs for severe heart attacks and, the company says, for rarer patterns indicating blocked arteries.
STAT•Katie Palmer11 Sept
STAT+: Right before midterms, Trump dangles $500 refunds for select ACA enrollees
The legal basis for the $500 checks, and who would get them, isn't entirely clear.
STAT•Bob Herman and Tara Bannow10 Sept
Platinum-based chemotherapy in childhood causes mutations that age the liver
Platinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumors
STAT•Annalisa Merelli10 Sept
Why two promising heart drugs flopped and what’s next
This week on "The Readout LOUD" podcast: Two experimental drugs were heralded as the next era in heart disease treatment — why did they fail?
STAT•Adam Feuerstein, Elaine Chen,and Allison DeAngelis10 Sept
STAT+: The gifts from pharma companies that keep on giving
There has been rancorous debate over doctors accepting free gifts and speaking fees from pharma companies. That doesn't mean doctors have reconsidered.
STAT•Ed Silverman10 Sept
STAT+: Can AI save rural health care?
Nominees for top federal health roles to face Congress, and Trump officials are betting on AI to help save rural health care.
STAT•John Wilkerson10 Sept
STAT+: FDA expands Bayer lung cancer drug approval
UniQure readout tests durability of benefits, an AI effort to manage heart failure, and more biotech news from The Readout
STAT•Meghana Keshavan10 SeptSTAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks
STAT•Ed Silverman10 SeptSTAT+: Cancer medicines remain in short supply across the U.S., survey finds
An ongoing shortage of cancer medications continues to force leading cancer centers around the U.S. to seek work-around strategies to treat patients and a majority also report that clinical trials…
STAT•Ed Silverman10 Sept
Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree
Feds invest in AI for heart failure, vaccines and this year's midterms, and more health news from Morning Rounds
STAT•O. Rose Broderick10 Sept
STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
A Roivant lung disease drug has succeeded in a mid-stage study. But the drug’s origins are another fascinating aspect to the story.
STAT•Adam Feuerstein10 Sept
STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical trial of its gene therapy for Huntington’s disease.
STAT•Adam Feuerstein10 Sept